Retatrutide
Triple hormone boost for maximum weight loss
- Weight Loss/Fat Loss (GLP triple agonist)
Thyroid C-cell tumor risk: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — based on rodent carcinogenicity data; human relevance uncertain Pancreatitis warning: Discontinue if pancreatitis is suspected; monitor for persistent severe abdominal pain Significant lean mass loss (~10% of weight lost): Resistance training strongly recommended to preserve muscle mass during treatment Gastroparesis risk: May significantly slow gastric emptying; use caution in patients with pre-existing gastroparesis or GI motility disorders
Mechanism of Action
Retatrutide is a triple receptor agonist that simultaneously activates three hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple activation enhances insulin secretion in a glucose-dependent manner, suppresses appetite through central nervous system pathways, and increases energy expenditure through glucagon's thermogenic effects on the liver and adipose tissue. Key Pathways: GLP-1 receptor activation: reduces appetite, slows gastric emptying, enhances glucose-dependent insulin secretion, GIP receptor activation: potentiates insulin secretion, may improve fat metabolism and energy balance, Glucagon receptor activation: increases hepatic glucose output acutely but promotes lipid oxidation, thermogenesis, and energy expenditure The combined activation of all three receptors produces substantial weight loss (up to 24-26% of body weight in trials) that exceeds what single or dual agonists achieve, likely because glucagon receptor activation adds an energy expenditure component on top of appetite suppression. This mechanism also explains the observed improvements in liver fat (up to 86% reduction in MASLD patients), glycemic control (HbA1c reductions up to 2.16%), and metabolic parameters like blood pressure and lipid profiles.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Retatrutide protocols — frequency, timing, cycle length, reconstitution & research
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite / Early satiety
- Lean mass / Muscle loss
- Gastroparesis risk
- Pancreatitis